Holen Sie sich die Stockscreener-App
29.28
3.13%
0.89
Handel nachbörslich:
29.25
-0.03
-0.10%
Schlusskurs vom Vortag:
$28.39
Offen:
$28
24-Stunden-Volumen:
15.52M
Relative Volume:
1.20
Marktkapitalisierung:
$6.83B
Einnahmen:
$2.35B
Nettoeinkommen (Verlust:
$128.37M
KGV:
56.08
EPS:
0.5221
Netto-Cashflow:
$57.42M
1W Leistung:
+4.98%
1M Leistung:
-5.79%
6M Leistung:
+37.21%
1J Leistung:
-45.01%
1-Tages-Spanne:
$27.31
$29.65
1-Wochen-Bereich:
$27.31
$31.81
52-Wochen-Spanne:
$13.74
$65.30
Hims Hers Health Inc Stock (HIMS) Company Profile
Firmenname
Hims Hers Health Inc
Sektor
Telefon
415-851-0195
Adresse
2269 CHESTNUT ST, SAN FRANCISCO
Compare HIMS vs TAK, TEVA, HLN, ZTS, UTHR
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
HIMS
Hims Hers Health Inc
|
29.28 | 6.62B | 2.35B | 128.37M | 57.42M | 0.5221 |
TAK
Takeda Pharmaceutical Co Adr
|
18.59 | 60.07B | 29.91B | 1.30B | 3.49B | 0.4056 |
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
40.22 | 45.50B | 17.53B | 1.58B | 444.18M | 1.3457 |
HLN
Haleon Plc Adr
|
9.22 | 40.06B | 14.54B | 2.22B | 2.58B | 0.4871 |
ZTS
Zoetis Inc
|
70.27 | 29.59B | 9.51B | 2.64B | 2.14B | 6.0361 |
UTHR
United Therapeutics Corp
|
472.21 | 20.99B | 3.17B | 1.29B | 1.01B | 27.09 |
Hims Hers Health Inc Stock (HIMS) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-04-24 | Eingeleitet | JP Morgan | Overweight |
| 2026-03-10 | Hochstufung | BofA Securities | Underperform → Neutral |
| 2026-03-10 | Hochstufung | Citigroup | Sell → Neutral |
| 2026-03-09 | Hochstufung | Needham | Hold → Buy |
| 2026-02-24 | Herabstufung | BTIG Research | Buy → Neutral |
| 2026-01-12 | Eingeleitet | Evercore ISI | In-line |
| 2025-12-09 | Eingeleitet | Barclays | Overweight |
| 2025-10-21 | Eingeleitet | KeyBanc Capital Markets | Sector Weight |
| 2025-06-23 | Herabstufung | Needham | Buy → Hold |
| 2025-06-04 | Bestätigt | Needham | Buy |
| 2025-04-29 | Herabstufung | TD Cowen | Buy → Hold |
| 2025-02-18 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2025-01-10 | Herabstufung | Citigroup | Neutral → Sell |
| 2025-01-07 | Eingeleitet | BTIG Research | Buy |
| 2024-12-17 | Eingeleitet | Morgan Stanley | Overweight |
| 2024-11-14 | Herabstufung | BofA Securities | Buy → Underperform |
| 2024-08-22 | Eingeleitet | Needham | Buy |
| 2024-08-09 | Herabstufung | Imperial Capital | Outperform → In-line |
| 2024-05-22 | Herabstufung | Citigroup | Buy → Neutral |
| 2024-04-16 | Herabstufung | Jefferies | Buy → Hold |
| 2024-04-10 | Eingeleitet | Canaccord Genuity | Buy |
| 2024-02-28 | Hochstufung | Imperial Capital | In-line → Outperform |
| 2024-02-26 | Eingeleitet | Leerink Partners | Market Perform |
| 2023-12-07 | Eingeleitet | Imperial Capital | In-line |
| 2023-07-28 | Eingeleitet | TD Cowen | Outperform |
| 2023-04-11 | Eingeleitet | Robert W. Baird | Neutral |
| 2023-02-09 | Hochstufung | Jefferies | Hold → Buy |
| 2022-11-08 | Hochstufung | BofA Securities | Neutral → Buy |
| 2022-11-08 | Hochstufung | SVB Leerink | Mkt Perform → Outperform |
| 2022-10-17 | Herabstufung | Piper Sandler | Overweight → Neutral |
| 2022-09-07 | Eingeleitet | Truist | Hold |
| 2022-07-15 | Eingeleitet | SVB Leerink | Underperform |
| 2022-04-14 | Eingeleitet | Guggenheim | Buy |
| 2022-04-01 | Fortgesetzt | Credit Suisse | Outperform |
| 2022-03-10 | Eingeleitet | Deutsche Bank | Hold |
| 2021-12-02 | Eingeleitet | Jefferies | Hold |
| 2021-11-11 | Hochstufung | Piper Sandler | Neutral → Overweight |
| 2021-07-06 | Eingeleitet | BofA Securities | Neutral |
| 2021-05-20 | Hochstufung | Credit Suisse | Neutral → Outperform |
| 2021-04-21 | Eingeleitet | Truist | Hold |
| 2021-03-09 | Eingeleitet | Credit Suisse | Neutral |
| 2021-03-02 | Hochstufung | Citigroup | Neutral → Buy |
| 2021-02-17 | Eingeleitet | Citigroup | Neutral |
| 2021-02-12 | Eingeleitet | Piper Sandler | Neutral |
| 2021-02-08 | Eingeleitet | Tigress Financial | Buy |
Alle ansehen
Hims Hers Health Inc Aktie (HIMS) Neueste Nachrichten
INVESTOR DEADLINE: Hims & Hers Health, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit Before November 2, 2026 DeadlineHIMS - TMX Newsfile
Hims Launches AI-Native Weight Loss Care Platform Featuring Closed-Loop Action Engine and Clinical Escalation - HIT Consultant
Hims & Hers Health Inc (HIMS) Stock Up 3.1% and Still Undervalued -- GF Score: 77/100 - GuruFocus
Kaplan Fox Alerts Investors of Hims & Hers Health, Inc. (NYSE: HI - The National Law Review
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Hims & Hers Health, Inc. of Class Action Lawsuit and Upcoming DeadlinesHIMS - PR Newswire
Hims & Hers Slides Nearly 7% as Legal Pressure Adds to Its Growing List of Risks - MarketBeat
10 Health Care Stocks Whale Activity In Today’s Session - Benzinga
DEADLINE ALERT for YSS, HIMS, UNCY, and PZZA: The Law - GlobeNewswire
Bronstein, Gewirtz & Grossman LLC Urges Hims & Hers Health, - GlobeNewswire
Hims & Hers Health Shareholder Alert: ClaimsFiler Reminds - GlobeNewswire
Hims & Hers (HIMS) Shareholder Alert: Investigation of Potential Fiduciary Duty BreachesKehoe Law Firm, P.C. - The National Law Review
SHAREHOLDER ALERT Bernstein Liebhard LLP Announces A - GlobeNewswire
Why Better Health Demands More than a Chatbot - Hims & Hers Newsroom
Kaplan Fox Alerts Hims & Hers Health, Inc. (NYSE: HIMS) Investors - The National Law Review
Hims & Hers Health (NYSE: HIMS) Faces Securities Class Action After FTC Lawsuit Reveal Drives Stock Sharply Lower -- HBSS - PR Newswire
Shareholders who lost money in shares of acquired Doximity, Inc. (NYSE: DOCS) should contact Wolf Haldenstein Immediately - GlobeNewswire Inc.
Why Hims & Hers Health, Inc. (HIMS) Dipped More Than Broader Market Today - finance.yahoo.com
Hims and Hers Is Scaling Rapidly, But Management Needs To Address The Difficult Questions - finance.yahoo.com
Bragar Eagel & Squire, P.C. Reminds Hims & Hers Health, - GlobeNewswire
HIMS Shareholder Alert: Investigation of Potential - GlobeNewswire
HIMS Investors Have Opportunity to Lead Hims & Hers Health, Inc. Securities Fraud Lawsuit with SBS Law - The National Law Review
Lead Plaintiff Deadlines in Shareholder Class Action - GlobeNewswire
Kaplan Fox Reminds Hims & Hers Health, Inc. (NYSE: HIMS) Investors With Significant Losses to Seek a Leadership Role Before Deadline on November 2, 2026 - Barchart.com
Hims & Hers Health, Inc. Securities Fraud Class Action - GlobeNewswire
Hims & Hers Suit Spotlights Health Data-Sharing Privacy Risks - Law360
Hims & Hers Health, Inc. (HIMS) Investors: November 2, 2026, Filing Deadline in Securities Fraud Class ActionContact Kessler Topaz Meltzer & Check, LLP - Morningstar
Hims & Hers Just Went Negative on Profit. Twice. - finance.yahoo.com
Deadline Alert: Hims & Hers Health, Inc. (HIMS) - GlobeNewswire
HIMS INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announc - The National Law Review
Hims & Hers Health, Inc. (HIMS) Shareholders Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit - PR Newswire
HIMS & HERS HEALTH, INC. (HIMS) SHAREHOLDER ALERT Bernstein - GlobeNewswire
Shareholders who lost money in shares of acquired Hims & - GlobeNewswire
Kaplan Fox Reminds Hims & Hers Health, Inc. (NYSE: HIMS) Investor - The National Law Review
Hims and Hers Health (HIMS): The Smallcap Stocks Name Everyone's Asking About - Kalkine Media
Hims & Hers Health Inc (HIMS) Shares Surge 4.9% -- What GF Score of 77 Tells Investors - GuruFocus
THNR's Weight-Loss Index Swaps Hims & Hers for Gilead - ETF Database
Investors Heavily Search Hims & Hers Health, Inc. (HIMS): Here is What You Need to Know - finance.yahoo.com
HIMS INVESTOR DEADLINE: Hims & Hers Health, Inc. Investors - GlobeNewswire
ROSEN, A LEADING LAW FIRM, Encourages Hims & Hers Health, - GlobeNewswire
ROSEN, A LEADING LAW FIRM, Encourages Hims & Hers Health, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important Deadline in Securities Class Action - GlobeNewswire Inc.
Hims & Hers Health, Inc. Class Action Lawsuit Seeks - GlobeNewswire
Hims & Hers Chief Legal Officer Soleil Boughton Sells 6,236 Shares - finance.yahoo.com
Hims & Hers Health Shareholder Alert: ClaimsFiler Reminds Investors With Losses In Excess Of $100,000 Of Lead Plaintiff Deadline In Class Action Lawsuit Against Hims & Hers Health, Inc.HIMS - PR Newswire
Kaplan Fox Alerts Hims & Hers Health, Inc. (NYSE: HIMS) Investors to Seek Leadership in a Securities Fraud Lawsuit by November 2, 2026 - FinancialContent
Hims & Hers Health COO Chi Michael Sells 14,027 Shares at $28.39 on September 15, 2026 - Kalkine Media
Hims & Hers Health CFO Oluyemi Okupe Sells 12,313 Shares Under Rule 10b5-1 Plan - Kalkine Media
Robbins LLP Urges HIMS Stockholders Who Lost Money Investing in Hims & Hers Health, Inc. to Contact the Firm for Information About Leading the Class Action - Business Wire
Class-action lawsuit filed against Hims & Hers following FTC complaint - Digital Watch Observatory
HIMS INVESTOR DEADLINE: Hims & Hers Health, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit Before November 2, 2026 Deadline, Robbins Geller Rudman & Dowd LLP Announces - daily-tribune.com
What’s Changing Around Hims & Hers Health (NYSE:HIMS) Right Now? - Kalkine Media
Hims & Hers Health (HIMS) Investors with Substantial Losses Have Opportunity to Lead Hims & Hers Class Action Lawsuit Before November 2, 2026 Deadline - PR Newswire
Finanzdaten der Hims Hers Health Inc-Aktie (HIMS)
Umsatz
Nettogewinn
Free Cashflow
ENV
2.46%
0.73%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):